Active Ingredient History

  • Now
Tasquinimod is an experimental drug currently being investigated for the treatment of solid tumors. Tasquinimod has been mostly studied in prostate cancer, but its mechanism of action suggests that it could be used to treat other cancers. Castration-resistant prostate cancer (CRPC), formerly called hormone-resistant or hormone-refractory prostate cancer, is prostate cancer that grows despite medical or surgical androgen deprivation therapy. Tasquinimod targets the tumor microenvironment and counteracts cancer development by inhibiting angiogenesis and metastasis and by modulating the immune system. It is now in phase III development, following successful phase II trial outcomes.   Wikipedia

  • SMILES: COc1cccc2N(C)C(=O)C(=C(O)c12)C(=O)N(C)c3ccc(cc3)C(F)(F)F
  • Mol. Mass: 406.36
  • ALogP: 3.55
  • ChEMBL Molecule:
More Chemistry
4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-((4-trifluoromethyl)phenyl)-1,2-dihydroquinoline-3-carboxamide | abr-215050 | tasq | tasquinimod


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue